Hormonal
GLP-1 receptor agonists (GLP-1-RAs) produce significant weight loss (up to 14.9%) and improved glycemic control (HbA1c reduction 0.8-1.8%) in adults with obesity or type 2 diabetes through mechanisms involving delayed gastric emptying, increased satiety, and glucose-dependent insulin secretion.
If you have obesity or type 2 diabetes and lifestyle changes haven't been enough, GLP-1 medications like semaglutide or liraglutide are highly effective. They work by mimicking a hormone that tells your brain you're full and slows down digestion. Expect some stomach upset at first, but starting with a low dose and increasing slowly helps. These drugs can lead to significant weight loss (around 15% in some cases) and better blood sugar control, especially if you have heart disease risk factors.
GLP-1-RAs function similarly to naturally occurring incretins. They stimulate insulin secretion in response to glucose levels, inhibit glucagon release, delay stomach emptying, and generate a sense of fullness via brain pathways. Head-to-head clinical studies have indicated that GLP-1-RAs outperform conventional antidiabetic medicines in terms of glycemic management and weight reduction.
Why this rating
The paper cites multiple large-scale randomized controlled trials (STEP-1, SUSTAIN-7, LEADER) and meta-analyses.
Source
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review
Khalid M Hamed et al. · Cureus · 2024
DOI 10.7759/cureus.68390
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →